The rise of cell and gene therapies is marking a pivotal moment in the development of contemporary medicine, with applications extending across a wide array of therapeutic areas such as diabetes, autoimmune disorders, and oncology. Donna Christopher, the Global Vice President of Operations at Alma Clinical Services, highlighted the growing significance of this field during her statement on October 17, 2024. She noted the immense potential offered by the expanding market for cell and gene therapies, but also pointed out the considerable challenges faced in managing the complex international clinical trial supply chains. These chains, which often involve handling highly volatile and valuable Investigational Medicinal Products (IMP), could present significant hurdles to the successful execution of studies.
In this rapidly advancing sector, the need for precise and secure handling of sensitive biological materials has driven the growth of related industries, particularly cryogenic technology. A key innovation to address this challenge is the cryogenic multi-use dewars introduced by CSafe Company. Launched in April 2024, CSafe’s range of cryogenic storage solutions, known as the CGT Cryo Series, is designed to meet the specific needs of the cell and gene therapy market. These devices, capable of maintaining ultra-low temperatures below -150°C, offer critical advantages in transporting sensitive biological materials. From pre-frozen biologic substances to regenerative medicine, immunotherapies, stem cells, and CAR-T cells, the reusable dewars and high-impact-resistant shipping cases provide a secure, reliable solution for the complex transportation requirements of the cell and gene therapy sector.
The cryogenic technology market is poised for significant growth, reflecting the increasing demand for safe transport and storage solutions. The global cryogenic labels market, for instance, was valued at US$ 1.11 billion in 2023 and is expected to reach around US$ 2.16 billion by 2034, growing at a compound annual growth rate (CAGR) of 6.25% from 2025 to 2034. This growth is driven by the rising need for cryogenic containers that ensure the integrity of biological materials during transit, as well as the increasing prevalence of cell and gene therapies.
Get All the Details on Our Solutions – Brochure Download: https://www.towardspackaging.com/download-brochure/5422
Further emphasizing the importance of cryogenic technology, a notable industry acquisition occurred in November 2024. Standex International Corporation (SI) acquired Custom Biogenic Systems (CBS), a Michigan-based manufacturer of innovative cryogenic equipment, for approximately $6.2 million in cash. CBS, which specializes in cryogenic storage solutions, will now become part of SI’s scientific business division, further expanding its capabilities and strengthening its position in the biopharmaceutical sector. This acquisition represents a key move in ensuring the continued development of cutting-edge cryogenic solutions, crucial for supporting the growing cell and gene therapy market.
Invest in Our Premium Strategic Solution: https://www.towardspackaging.com/price/5422
Get the latest insights on packaging industry segmentation with our Annual Membership – https://www.towardspackaging.com/get-an-annual-membership
If you have any questions, please feel free to contact us at sales@towardspackaging.com
Browse our Brand-New Journal:
https://www.towardshealthcare.com
https://www.towardsautomotive.com
For Latest Update Follow Us: https://www.linkedin.com/company/towards-packaging/
Get Our Freshly Printed Chronicle: https://www.packagingwebwire.com/